These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 35456436)

  • 1. Technological Advances:
    Akabari R; Qin D; Hussaini M
    Genes (Basel); 2022 Apr; 13(4):. PubMed ID: 35456436
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Accurate Detection and Quantification of FLT3 Internal Tandem Duplications in Clinical Hybrid Capture Next-Generation Sequencing Data.
    Tung JK; Suarez CJ; Chiang T; Zehnder JL; Stehr H
    J Mol Diagn; 2021 Oct; 23(10):1404-1413. PubMed ID: 34363960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of FLT3 internal tandem duplication in targeted, short-read-length, next-generation sequencing data.
    Spencer DH; Abel HJ; Lockwood CM; Payton JE; Szankasi P; Kelley TW; Kulkarni S; Pfeifer JD; Duncavage EJ
    J Mol Diagn; 2013 Jan; 15(1):81-93. PubMed ID: 23159595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hybridization capture-based next generation sequencing reliably detects FLT3 mutations and classifies FLT3-internal tandem duplication allelic ratio in acute myeloid leukemia: a comparative study to standard fragment analysis.
    He R; Devine DJ; Tu ZJ; Mai M; Chen D; Nguyen PL; Oliveira JL; Hoyer JD; Reichard KK; Ollila PL; Al-Kali A; Tefferi A; Begna KH; Patnaik MM; Alkhateeb H; Viswanatha DS
    Mod Pathol; 2020 Mar; 33(3):334-343. PubMed ID: 31471587
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection the Frequency and Characteristics of FLT3 Internal Tandem Duplication Mutations by Capillary Electrophoresis Assay and Next-Generation Sequencing in.
    Ma L; Cao Y; Jiang Y; Cong X; Lu S; Shen J; Liu Q; Han C; Zhan Y; Cao Y
    Clin Lab; 2016 Oct; 62(10):2065-2072. PubMed ID: 28164543
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A clinical grade sequencing-based assay for CEBPA mutation testing: report of a large series of myeloid neoplasms.
    Behdad A; Weigelin HC; Elenitoba-Johnson KS; Betz BL
    J Mol Diagn; 2015 Jan; 17(1):76-84. PubMed ID: 25468431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted Informatics for Optimal Detection, Characterization, and Quantification of FLT3 Internal Tandem Duplications Across Multiple Next-Generation Sequencing Platforms.
    Tsai HK; Brackett DG; Szeto D; Frazier R; MacLeay A; Davineni P; Manning DK; Garcia E; Lindeman NI; Le LP; Lennerz JK; Gibson CJ; Lindsley RC; Kim AS; Nardi V
    J Mol Diagn; 2020 Sep; 22(9):1162-1178. PubMed ID: 32603763
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical significance of FLT3-ITD/CEBPA mutations and minimal residual disease in cytogenetically normal acute myeloid leukemia after hematopoietic stem cell transplantation.
    Wang H; Li XQ; Chu TT; Han SY; Qi JQ; Tang YQ; Qiu HY; Fu CC; Tang XW; Ruan CG; Wu DP; Han Y
    J Cancer Res Clin Oncol; 2021 Sep; 147(9):2659-2670. PubMed ID: 33550446
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic significance of FLT3 internal tandem duplication, nucleophosmin 1, and CEBPA gene mutations for acute myeloid leukemia patients with normal karyotype and younger than 60 years: a systematic review and meta-analysis.
    Port M; Böttcher M; Thol F; Ganser A; Schlenk R; Wasem J; Neumann A; Pouryamout L
    Ann Hematol; 2014 Aug; 93(8):1279-86. PubMed ID: 24801015
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A DNA pool of FLT3-ITD positive DNA samples can be used efficiently for analytical evaluation of NGS-based FLT3-ITD quantitation - Testing several different ITD sequences and rates, simultaneously.
    Mezei ZA; Tornai D; Földesi R; Madar L; Sümegi A; Papp M; Antal-Szalmás P
    J Biotechnol; 2019 Sep; 303():25-29. PubMed ID: 31302157
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ITDetect: a method to detect internal tandem duplication of FMS-like tyrosine kinase (FLT3) from next-generation sequencing data with high sensitivity and clinical application.
    Lee S; Sun CH; Jang H; Kim D; Yoon SS; Koh Y; Na SC; Cho SI; Kim MJ; Seong MW; Byun JM; Yun H
    BMC Bioinformatics; 2023 Feb; 24(1):62. PubMed ID: 36823555
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparative study of next-generation sequencing and fragment analysis for the detection and allelic ratio determination of FLT3 internal tandem duplication.
    Kim JJ; Lee KS; Lee TG; Lee S; Shin S; Lee ST
    Diagn Pathol; 2022 Jan; 17(1):14. PubMed ID: 35081962
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ITD assembler: an algorithm for internal tandem duplication discovery from short-read sequencing data.
    Rustagi N; Hampton OA; Li J; Xi L; Gibbs RA; Plon SE; Kimmel M; Wheeler DA
    BMC Bioinformatics; 2016 Apr; 17():188. PubMed ID: 27121965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NPM1, FLT3 and CEBPA mutations in pediatric patients with AML from Argentina: incidence and prognostic value.
    Rubio P; Campos B; Digiorge JA; Gallego MS; Medina A; Rossi JG; Felice MS; Alonso CN
    Int J Hematol; 2016 Nov; 104(5):582-590. PubMed ID: 27436336
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.
    Schlenk RF; Döhner K; Krauter J; Fröhling S; Corbacioglu A; Bullinger L; Habdank M; Späth D; Morgan M; Benner A; Schlegelberger B; Heil G; Ganser A; Döhner H;
    N Engl J Med; 2008 May; 358(18):1909-18. PubMed ID: 18450602
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical evaluation of panel testing by next-generation sequencing (NGS) for gene mutations in myeloid neoplasms.
    Au CH; Wa A; Ho DN; Chan TL; Ma ES
    Diagn Pathol; 2016 Jan; 11():11. PubMed ID: 26796102
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CEBPA single mutation can be a possible favorable prognostic indicator in NPM1 and FLT3-ITD wild-type acute myeloid leukemia patients with intermediate cytogenetic risk.
    Park SH; Chi HS; Cho YU; Jang S; Park CJ
    Leuk Res; 2013 Nov; 37(11):1488-94. PubMed ID: 24054719
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nanopore Targeted Sequencing for Rapid Gene Mutations Detection in Acute Myeloid Leukemia.
    Cumbo C; Minervini CF; Orsini P; Anelli L; Zagaria A; Minervini A; Coccaro N; Impera L; Tota G; Parciante E; Conserva MR; Spinelli O; Rambaldi A; Specchia G; Albano F
    Genes (Basel); 2019 Dec; 10(12):. PubMed ID: 31835432
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations.
    Green CL; Koo KK; Hills RK; Burnett AK; Linch DC; Gale RE
    J Clin Oncol; 2010 Jun; 28(16):2739-47. PubMed ID: 20439648
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Internal tandem duplication mutations in the tyrosine kinase domain of FLT3 display a higher oncogenic potential than the activation loop D835Y mutation.
    Marhäll A; Heidel F; Fischer T; Rönnstrand L
    Ann Hematol; 2018 May; 97(5):773-780. PubMed ID: 29372308
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.